A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer.

Trial Profile

A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Sapitinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Jun 2012 Actual patient number added 17 according to ClinicalTrials.gov.
    • 25 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top